Cargando…
Author Correction: Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study
Autores principales: | Locatelli, Franco, Zugmaier, Gerhard, Mergen, Noemi, Bader, Peter, Jeha, Sima, Schlegel, Paul-Gerhardt, Bourquin, Jean-Pierre, Handgretinger, Rupert, Brethon, Benoit, Rossig, Claudia, Chen-Santel, Christiane |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873230/ https://www.ncbi.nlm.nih.gov/pubmed/33563903 http://dx.doi.org/10.1038/s41408-021-00413-7 |
Ejemplares similares
-
Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study
por: Locatelli, Franco, et al.
Publicado: (2020) -
Correction: Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study
por: Locatelli, Franco, et al.
Publicado: (2021) -
Blinatumomab in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis
por: Locatelli, Franco, et al.
Publicado: (2022) -
Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia
por: Gore, Lia, et al.
Publicado: (2018) -
CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment
por: Mejstríková, E., et al.
Publicado: (2017)